Incyte reports 24-week data for Opzelura cream in moderate atopic dermatitis
Tweet Send to a Friend
Incyte (NASDAQ: INCY) announced 24-week results from its Phase 3 TRuE-AD4 study of Opzelura cream for adults with moderate atopic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
